CAMBRIDGE, United Kingdom, April 03, 2024 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small...
Astex Pharmaceuticals, a pharmaceutical company developing small molecule therapeutics for oncology and diseases of the central nervous system, has earned a milestone payment from AstraZeneca for the first commercial sale of Truqap plus Faslodex for HR-positive, HER2-negative locally advanced or metastatic breast cancer in the U.S. following the U.S. FDA’s approval.
Taiho and Astex Announce Data Presentations at the 65th ASH Annual Meeting
Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
Cambridge, UK, 8 August 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA). The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.
Astex Pharmaceuticals – a company which concentrates on the development of small molecule therapeutics – has formed a partnership with the Medicines Discovery Institute, Cardiff University (MDI).
CAMBRIDGE, United Kingdom, Dec. 31, 2022 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list. Dr. Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery.
The European Medicines Agency (EMA) has accepted Otsuka Pharmaceutical and Astex Pharmaceuticals’ marketing authorisation application (MAA) for an oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the initial treatment of adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy.
PLEASANTON, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (Astex) today announce that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the initial treatment of adults with acute myeloid leukemia (AML) who are not candidates for standard induction chemotherapy.
PLEASANTON, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. announces today top-line results from the ASCERTAIN phase 3 study evaluating oral decitabine and cedazuridine fixed-dose combination (ASTX727 or DEC-C) tablets versus IV decitabine in adults with AML who are not candidates to receive standard induction chemotherapy.